Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002104 · ClinicalTrials.gov registry record · Phase 1
Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
A Phase 1 study, sponsored by Aaron Diamond AIDS Research Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002104: Completed Phase 1 study, sponsored by Aaron Diamond AIDS Research Center.
NCT00002104 is a Phase 1 study that has completed, run by Aaron Diamond AIDS Research Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002104, a Phase 1 study, has completed, sponsored by Aaron Diamond AIDS Research Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To demonstrate, in patients with tubercular or nontubercular mycobacterium infections with or without HIV infection, the safety of thalidomide use as judged by symptoms, physical exam, and studies of microbiologic, immunologic, hematologic, renal, and hepatic status. To demonstrate efficacy of the drug as judged by status of fever, nutrition, tuberculosis lesions, and immune responses.
Interventions
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002104 record still lists
NCT00002104 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Thalidomide is the first listed.
NCT00002104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002104 about?
NCT00002104 is a clinical study titled "Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV". To demonstrate, in patients with tubercular or nontubercular mycobacterium infections with or without HIV infection, the safety of thalidomide use as judged by symptoms, physical exam, and studies of microbiologic, immunologic, hematologic, renal, and hepatic status. To demonstrate efficacy of the d...
What is the current status of trial NCT00002104?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002104?
The interventions under investigation include: Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00002104?
This trial is sponsored by Aaron Diamond AIDS Research Center, which has 1 total clinical trials registered on ClinicalTrials.gov.